---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-21-002825"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2021-07-06T23:59:59+00:00"
generated_at: "2026-06-30T07:08:49.870375+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte shareholders approve 50B common share authorization increase and bylaw amendment

## Summary
- Authorized common stock increased to 50 billion shares ($0.0001 par); preferred stock to 10 million shares.
- All seven director nominees elected; broker non-votes of ~701M shares.
- 2021 Equity Incentive Plan approved: 565.7M for, 116.4M against, 20.6M abstain.
- Armanino LLP ratified as independent auditor for FY ending April 30, 2022.
- Bylaw Amendment No. 4 adopted, adding cumulative voting rights for directors.

## SEC filing metadata
- accession: 0001683168-21-002825
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2021-07-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316821002825/0001683168-21-002825-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316821002825/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-21-002825
- JSON: https://secwatch.observer/filing/0001683168-21-002825.json
- Plain text: https://secwatch.observer/filing/0001683168-21-002825.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.